Alphabiome Ltd

Based in Israel, Alphabiome Ltd delivers advanced microbiome intelligence solutions through AI technology, focusing on enhancing precision medicine and optimizing drug efficacy for healthcare providers and pharmaceutical companies. Alphabiome Ltd specializes in microbiome analytics aimed at improving drug development and patient outcomes. Founded in 2022, the company has conducted one deal to date. Its most recent funding round was a Seed round on May 7, 2025, raising USD 8.

00 mn in total, which reflects the full amount raised by the company. Dr. Yaniv Altshuler, CEO and Founder of Alphabiome Ltd Alphabiome specializes in AI-powered microbiome intelligence solutions aimed at enhancing precision medicine. The company’s core product offerings center around its proprietary technology that analyzes microbial DNA to extract genetic biomarkers, enabling it to predict the efficacy of various biological and biochemical treatments.

This technology identifies over 100,000 biomarkers, facilitating optimized drug development and personalized treatment selection. Alphabiome's solutions are primarily targeted at pharmaceutical companies and healthcare providers seeking to enhance drug efficacy and patient outcomes. The applications span across multiple therapeutic areas, including nutritional additives for livestock, with the technology validated in substantial studies in North America and Europe, where it addresses critical health and environmental challenges. Alphabiome generates revenue through partnerships and collaborations with pharmaceutical companies, leveraging its microbiome insights to improve drug response predictions.

The business model encompasses B2B transactions, where clients access the proprietary platform for drug development and personalized medicine solutions. Clients engage in structured agreements that may involve licensing fees or revenue-sharing arrangements based on the efficacy of the treatments developed using Alphabiome's technology. The company’s recent funding initiatives, such as securing USD 8. 00 mn to expand R&D, highlight its commitment to scaling operations and further developing its innovative solutions.

Specific pricing structures for products or services are not publicly disclosed, but the focus remains on delivering value through enhanced therapeutic outcomes and optimizing drug efficacy for its client base. In May 2025, Alphabiome Ltd raised USD 8. 00 mn in Seed funding led by AIX Venture. to enhance its microbiome analytics platform and support the development of new precision health solutions.

The funding will be utilized to improve existing products and potentially launch new solutions targeting the healthcare market. The company aims to expand its presence in North America and Europe and will strategically seek to enter additional markets by the end of 2026.